ehealth radio network
Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

July 22, 2021

 

Douglas_Dieterich6b6hd.png

 

Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, and professor of medicine for the Division of Liver Disease, Icahn School of Medicine at Mount Sinai joins eHealth Radio and the Health News and Technology Channels to discuss noninvasive liver screening to halt the progression of liver disease.


Listen to interview with host Eric Michaels and guest Dr. Douglas Dieterich discuss the following:

  1. Please share with us the importance of ongoing assessment of liver stiffness and fat as part of a liver health assessment?
  2. What role does FibroScan play in the diagnoses of chronic liver diseases and cirrhosis?
  3. What is the risk of hepatocellular carcinoma (HCC) in people with long-term liver diseases, and if the liver is scarred by infection with hepatitis B or hepatitis C?
  4. Tell us more about the use of FibroScan in hospital settings to improve outcomes and reduce costs in the assessment of liver disease.
  5. Where do you see this going in terms of management and improving outcomes?

Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.

He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.

Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.

Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.

Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.

Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

July 5, 2021

 

Jon_Gingrich_2021ah5vj.png

 

Jon Gingrich, the CEO of Echosens North America, a high-technology company offering the FibroScan family of products joins eHealth Radio and the Health News & Technology Channels.


Listen to interview with host Eric Michaels and guest Jon Gingrich discuss the following:

  1. Please share with us the ongoing need for liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans.

  2. Please tell our audiences about the 2021 Echosens corporate initiatives and its focus on halting the progression of non-alcoholic fatty liver disease (NAFLD), fibrosis and cirrhosis. Describe new goals and objectives for building on the progress that Echosens has made in 2020.
  3. Explain how Echosens plans to further expand the use of FibroScan technology in healthcare systems across America.

  4. Can you describe specific programs and services to help educate specialists on the role of FibroScan?

  5. How is Echosens helping payers and employers to understand the value of FibroScan?

  6. Tell us about Echosens’ FAST score implementation and what successes you are seeing as a result of its use.

  7. Explain how the COVID-19 pandemic has highlighted opportunities for Echosens to solve new problems, and support innovations that advance preventive care, address critical health care needs and improve outcomes for more Americans.
  8. What is Echosens’ focus to continue bringing this awareness of NAFLD diagnosis and treatment in a post-pandemic world?

About Jon Gingrich, CEO, Echosens North America

With more than 20 years of global medical device and health care sales, marketing and general management experience at AxoGen, Inc., Hologic, Inc., Boston Scientific Corporation and Unilever, N.V, Gingrich now leads the development and execution of the Echosens U.S. strategy for expanding the utilization of FibroScan® technology in the assessment of chronic liver disease. As a member of the broader global executive leadership team, he works to implement the Company’s transformation plan and shape the future of Echosens.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV

The way we experience healthcare has changed for good: A conversation with David McNeil of PatientPop

The way we experience healthcare has changed for good: A conversation with David McNeil of PatientPop

June 29, 2021

 

David_McNeilbjmnt.jpeg

 

David McNeil, President and COO of PatientPop, the first all-in-one practice growth platform joins eHealth Radio and the Health Care and Marketing Channels. On this episode, you will learn more about how technology is improving patient experience and helping practices grow.


Listen to interview with host Eric Michaels and guest David McNeil discuss the following:

  1. Can you introduce yourself, past companies you’ve worked at, and describe your role at PatientPop?
  2. Can you tell our listeners more about PatientPop and the solutions you provide for private practices?
  3. What are some of the pain points in healthcare that PatientPop is addressing?
  4. What is the biggest benefit to private practices with using PaitentPop's technology?
  5. Do you have any stories you can share with us about the successes of practices using PatientPop?
  6. What is in store for the future of PaitentPop?

David McNeil is President & COO at PatientPop, the market leader in practice growth technology platform that helps practices increase patient acquisition, retention and deliver exceptional patient experiences. With over a decade of SaaS leadership experience, David is responsible for leading all go-to-market functions and the growth strategy for the company.

Prior to assuming this role, David was Head of North America Sales at HubSpot responsible for driving growth across all segments. Over his time at HubSpot, David held various leadership positions including Global VP of Customer Selling, Global VP of Channel, and Global VP of Sales Strategy & Operations. Prior to joining HubSpot, David was responsible for leading the Business Development organization for Americas at Salesforce.com.

Over the years David has held several leadership roles building highly effective go-to-market teams that drive accelerated growth and deliver real value to prospects and customers. David is extremely passionate about building an inclusive, safe, and diverse culture where we people can grow together, win together and have fun together. He is a husband, a proud dad of four teenagers (and two dogs), and an active advisor to small/mid-size companies. He is also actively involved with several charitable organizations focused on the areas of cancer and mental health.

 

PatientPop_Logo.jpg

 

Website: patientpop.com

Social Media Links:
Facebook: facebook.com/PatientPopInc 
Instagram: instagram.com/patient_pop 
Twitter: twitter.com/patientpop

Hero: The Digital Caregiver

Hero: The Digital Caregiver

May 20, 2021

 

Michal_Levin_Hero_VP_of_Product_Headshot68kru...

 

Michal Levin, VP of Product at Hero, the IoT-connected device that automatically dispenses medication when you need it joins eHealth Radio and the Health News and Technology Channels.


Listen to interview with host Eric Michaels and guest Michal Levin discuss the following:

  1. Can you introduce yourself, past companies you’ve worked at and describe your role at Hero?
  2. Can you tell our listeners more about how Hero was created?
  3. How does Hero address the pain points of medication mismanagement?
  4. What are some steps that the healthcare industry can improve and reduce medication mismanagement?
  5. Each year, medication mismanagement costs the American health care system nearly $300 billion, is there anything that the government can do to make this more of a pressing issue?
  6. What’s in store for Hero in the next 60 days, 6-months, year?

Michal Levin is the VP of Product at Hero, aiming to help people manage their health better, and live their lives to the fullest. She is passionate about solving hard problems that make a difference in people’s lives, and over her career of more than 15 years has led UX and product across Google, Verily Life Sciences, Zoox, modu and more. She authored the book "Designing Multi-Device Experiences'' (O'Reilly Media) and several other publications, mentored dozens of startups, and spoke at local and global conferences. Michal is also the mom of two toddlers, an avid audible listener and a big fan of live music shows.

 

HERO_LOGO.png

 

Website: https://herohealth.com

Dr. Stephen Harrison Discusses Clinical Importance of FibroScan Technology

Dr. Stephen Harrison Discusses Clinical Importance of FibroScan Technology

May 8, 2021

 

sHarrison_May21.png

 

Dr. Stephen A. Harrison, gastroenterologist and hepatologist, joins eHealth Radio and the Health News & Technology Channels to discuss the role FibroScan technology has played in the management of patients with liver disease.


Listen to interview with host Eric Michaels and guest Dr. Stephen A. Harrison discuss the following:

  1. Please share with us the ongoing need for assessing liver stiffness and fat as part of a liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans, especially during the COVID-19 pandemic.

  2. How does FibroScan tie into your clinical workflow? How might other clinicians be able to utilize it?

  3. Tell us about the successes you are seeing as a result of the FibroScan FAST score implementation and the research you’ve gathered from it.
  4. What work is being done to improve any previous high screen failure rates? Has there been any improvement since late phase clinical trials?

  5. Do you have any patient stories that you could share with us about the success of monitoring liver stiffness and fat with FibroScan?

  6. What will your focus be on continuing to bring awareness of NAFLD diagnosis and treatment in a post-pandemic world?

  7. Where do you see this research going in terms of the management of liver disease and improving outcomes for patients?

Dr. Stephen A. Harrison, M.D., FACP, FAASLD, retired COL, USA, MC, gastroenterologist and hepatologist, medical director of Pinnacle Clinical Research, and visiting professor of Hepatology, University of Oxford.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

logo_echosens_gradient6xp78.png

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV

Bastille Delivers Zone Detection for Healthcare Sector

Bastille Delivers Zone Detection for Healthcare Sector

May 5, 2021

 

Bob_Baxley_20218895b.png

 

Bob Baxley, CTO at Bastille Networks a company that delivers enterprise threat detection through software-defined radio joins eHealth Radio and the Technology Channel.


Listen to interview with host Eric Michaels and guest Bob Baxley discuss the following:

  1. Can you provide our listeners a background on Bastille and why the company was created?
  2. What are some of the pain points in radio frequency that Bastille is addressing?
  3. How will radio frequency’s complexity in the workplace change as workers return based on the devices they bring and the devices that they may be asked to wear?
  4. What are the benefits of using Bastille's technology for zone detection to mitigate the unforeseen new threats from other contact tracing technologies?
  5. What are some steps that the healthcare industry can improve to protect facilities and patient data from adversaries?

For more than a decade, Dr. Bob Baxley has been a technology leader in implementing machine learning algorithms for software defined and cognitive radios. At Bastille, Bob serves as Chief Technology Officer where he leads the development of systems to sift through massive amounts of radio frequency data to protect enterprises from radio threats.

Prior to joining Bastille, Bob was the Director of the Software Defined Radio Lab at Georgia Tech, where he led basic and applied research projects for organizations including NSF, ONR, Army, DoD, Air Force and DARPA. He has published more than 100 peer-reviewed papers and patents, is the receipt of various research awards, and is a Senior Member of the IEEE. He also led the GTRI team that competed in the DARPA Spectrum Challenge and placed second out of 90 teams.

 

Bastille_Logo68yg6.png

 

Website: www.bastille.net

Social Media Links:
Twitter: twitter.com/bastillenet 
Linkedin: linkedin.com/company/bastille-networks

How the pandemic has accelerated innovation in healthcare: A conversation with Karly Rowe from Experian Health

How the pandemic has accelerated innovation in healthcare: A conversation with Karly Rowe from Experian Health

April 8, 2021

 

Karley_Rowe8x5o2.jpeg

 

Karly Rowe, Vice President of Patient Access, Identity & Care Management Product for Experian Health that works with more than 3,200 hospitals and 10,000 other healthcare organizations representing 500,000 plus providers to provide data-driven solutions that support revenue cycle management, identity management, patient engagement and care management joins eHealth Radio and the Health Care and Health News Channels.


Listen to interview with host Eric Michaels and guest Karly Rowe discuss the following:

  1. Can you tell us about Experian Health and your role within the company?
  2. Any discussion of healthcare today is framed by the COVID-19 pandemic. From your business, your line of sight, what has the pandemic put in the spotlight?
  3. In the early days of the pandemic, some of our healthcare organizations estimated 1,800 duplicate records were being created every 24 hours, so it is a fair bet that the numbers are even greater now as people flock to schedule vaccines. How does the growing volume of patient traffic challenge our healthcare systems?
  4. How would a shift to standardized medical records, possibly even a universal patient ID number, help healthcare systems and health outcomes?
  5. What direction is the industry headed and what pain points are you solving for as you look to the future?

Summary: While approximately 25% of patients used patient portals prior to COVID-19, more than 235 million adults will likely interact with a patient portal or telehealth service for the first time. This new interaction sparks opportunity – an opportunity for patients to think differently about the role they are taking/playing in managing their health and an opportunity for healthcare organizations to think about how to build on and advance this newly formed relationship.


Karly Rowe is responsible for the Patient Access, Identity, and Care Management product portfolios at Experian Health. Leveraging her diverse background across credit, retail, and healthcare, Karly is responsible for finding new ways to leverage Experian’s data and analytical capabilities to develop new, innovative solutions for the healthcare industry.

Karly holds a Masters of Business Administration from Arizona State University and a Bachelor’s degree in Marketing Management and Retail Management from Syracuse University. She resides in Scottsdale, Arizona with her husband and two sons.

 

Experian_Health_Stacked_RGBbp6av.jpg

 

Website: experian.com/healthcare

Social Media Links:
Twitter: twitter.com/Experian_Health
Linkedin: linkedin.com/company/experian

COVID-19 most frequently asked questions for returning to work

COVID-19 most frequently asked questions for returning to work

April 3, 2021

 

Dr_Nitin_Desaibh9m8.png

 

Dr. Nitin Desai, an Internal Medicine Physician practicing in North Carolina for over 24 years and the Chief Medical Officer of COVID PreCheck, a digital health passport related to COVID-19 joins eHealth Radio and the Health News Channel.


Listen to interview with host Eric Michaels and guest Dr. Nitin Desai discuss the following:

  1. Now that multiple vaccines are available, should employers go back to business as usual?
  2. As employees return to work what should they expect from their employers to safeguard their health and safety?
  3. What would you recommend business leaders do to support a safe return to work?
  4. You have advocated using the Swiss cheese model to create safe workplaces - can you explain how it works? How does it keep employees safe?
  5. How do you see technology playing a role in return-to-work?
  6. What do you want to leave our audience (employees and employers) with?

About Dr. Nitin Desai

  • Physician entrepreneur.
  • Cofounder of Health Wizz, a Digital Healthcare venture https://www.healthwizz.com/  focused on EMR interoperability and Employee wellness.
  • Launched https://www.covidprecheck.net to assist in reopening the USA during the 2020 COVID Pandemic.
  • COVID PreCheck creates safe spaces with a software solution for employees and the workplace.
  • Experienced Physician, Medical Staff leader, and Digital health entrepreneur

COVIDPrejpg8eora.jpg

Website: https://covidprecheck.net

Social Media Links:
Facebook: facebook.com/COVIDPreCheckApp
Linkedin: linkedin.com/company/covidprecheck
Twitter: twitter.com/CPrecheck

AntiLand-Establishing Better Happiness Socially

AntiLand-Establishing Better Happiness Socially

January 23, 2021

 

txjxL0_g_400x400.jpg

 

Dr. Adi Zief-Balteriski, PHD Behavioral Science Expert and advisory to AntiLand, a truly anonymous and secure group chats messenger app that helps you mask your secret identity, make friends online and meet new people joins eHealth Radio and the Mental Health Channel.


Listen to interview with host Eric Michaels & guest Dr. Adi Zief-Balteriski discuss the following:

  1. As an expert in behavioral health, what are some of the challenges people face using social media?
  2. How is AntiLand an alternative to other known platforms? How is it better?
  3. What are the benefits of being anonymous in the AntiLand community?
  4. What type of topics are trending and how can one be part of the dialogue?
  5. What three tips do you have for those wanting to establish a better well-being or a social tune-up in 2021?

Dr. Adi Zief-Balteriski, Ph.D., Behavioral Science Expert and Product Leader, Dr. Adi Zief-Balteriski is a psychologist and product expert. She applies her expertise as a behavioral science specialist in the field of community, wellness, technology and consumer behavior. She is also a researcher in the field of well-being, human computing interaction and technology and presents her work at universities and organizations in the Bay Area.

Previously, Adi opened a successful private practice and a consulting business and engaged in product consulting for consumer and well-being products. After working several years as a consultant for startup founders in the Bay Area, she shifted her focus towards the tech world. Adi began working on products at startups focused on the well-being of individuals and communities. Later, she worked as a product manager being part of the entire product lifecycle from ideation to launch.

Adi holds a Ph.D. in clinical psychology from Palo Alto University, L.L.B in Law and B.A in Business and IT from the Interdisciplinary Center. She is also the mother of two young children and passionate about making a positive impact on people’s well-being and advocating for the empowerment of women to succeed in modern society. She is an advisor to AntiLand.

 

AntiLand_LOGO.png

Website: www.antiland.com

BioSig Technologies increases efforts in Electrophysiology and Atrial Fibrillation

BioSig Technologies increases efforts in Electrophysiology and Atrial Fibrillation

January 6, 2021

 

Ken_Londonera8jau.png

 

Ken Londoner, the Chief Executive Officer, Founder and Director of BioSig Technologies that is working to develop and deliver the advanced signal processing solutions that will unlock the future of bio-electronic medicine, starting with the PURE EP™ System joins eHealth Radio and the Heart Health and Technology Channels.


Listen to interview with host Eric Michaels and guest Ken Londoner discuss the following:

  1. Tell us a little bit about BioSig, the company’s mission and its efforts with in the medtech industry.
  2. What does PURE EP help treat?
  3. What types of current technologies are being used to treat AFib and how does your technology differ?
  4. How is BioSig’s PURE EP reshaping the future of electrophysiology? How will this technology be used in hospitals, electrophysiology labs, and other institutions?
  5. Tell us a little about BioSig’s subsidiary, ViralClear, and its potential antiviral candidate to treat COVID-19 patients.

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

 

BioSig_Tech_logo8zc44.png

 

Website: www.biosig.com

Social Media Links:
Facebook: facebook.com/biosigtechnologies
Linkedin: linkedin.com/company/biosig-technologies-inc-
Twitter: twitter.com/BioSig_Tech

Podbean App

Play this podcast on Podbean App